As we enter 2025 with a new president in the White House and Republicans in control of both the House and the Senate, we can look forward to a significant shift in the landscape for oil & gas transactions. The second Trump...more
1/16/2025
/ Biden Administration ,
Clean Energy ,
Climate Change ,
Energy Policy ,
Energy Sector ,
Environmental Justice ,
Environmental Policies ,
Federal Trade Commission (FTC) ,
FERC ,
Fossil Fuel ,
Inflation Reduction Act (IRA) ,
Legislative Agendas ,
Natural Gas ,
Oil & Gas ,
Private Equity ,
Renewable Energy ,
Tariffs ,
Trump Administration
The energy transition posts a tremendous opportunity for private equity investors. The scale of the investment requirement makes private capital a “must have” and a broad spectrum of energy transition opportunities,...more
The year 2023 will be remembered as a challenging one for private equity (PE), with complexities to navigate on many fronts. Traditional debt financing was expensive and scarce, expectations on valuations were tricky to...more
3/12/2024
/ Antitrust Provisions ,
Carbon Capture and Sequestration ,
CFIUS ,
China ,
Corporate Transparency Act ,
Divestiture ,
Domestic Dealmaking ,
Drug Pricing ,
Energy Sector ,
Foreign Direct Investment ,
Foreign Investment ,
Greenhouse Gas Emissions ,
Healthcare ,
Investment ,
Life Sciences ,
Liquidity ,
Mergers ,
Non-Compete Agreements ,
Prescription Drugs ,
Private Equity ,
Private Equity Firms ,
Renewable Energy ,
Reporting Requirements ,
UK ,
Unions ,
Venture Capital
Rapid deployment of new technology is required to achieve ambitious greenhouse gas emissions reduction targets. The scope and diversity of deployment required will see participation by new market entrants and a likely...more
Biomethane is indistinguishable from natural gas and can be deployed as a drop-in renewable replacement to natural gas without the need for adaptation of network infrastructure or end-user equipment.
The scale of...more
The last 12 months have seen dramatic falls in fintech and payments valuations, but with the payments sector now a core part of the financial services ecosystem, strategic imperatives will continue to drive deals despite...more
Volatile technology stocks and rising interest rates put the brakes on fintech funding rounds and M&A in 2022. But even though investment activity fell from 2021’s highs, fintech deal volumes have remained well ahead of...more
Further to the Chancellor’s announcement on April 3, 2020, of the introduction of the Coronavirus Large Business Interruption Loan Scheme (CLBILS), the CLBILS that is aimed at larger U.K. businesses is now live and the...more
On April 3, 2020, the Chancellor announced the introduction of the Coronavirus Large Business Interruption Loan Scheme (CLBILS) to be made available to UK businesses with an annual turnover of between £45 million and £500...more
Rishi Sunak, the U.K. Chancellor, has announced an “unprecedented package of government-backed and guaranteed loans to support businesses” to get through the COVID-19 shock.
The main components of the U.K. rescue package...more
Medical device and diagnostics companies and laboratories should anticipate significant legal, regulatory and market changes in 2020 that will have a lasting impact on the industry. From revisions to how the government...more
1/8/2020
/ Acquisitions ,
Artificial Intelligence ,
Biotechnology ,
Centers for Medicare & Medicaid Services (CMS) ,
CFIUS ,
Department of Health and Human Services (HHS) ,
Digital Health ,
EU ,
Export Controls ,
Food and Drug Administration (FDA) ,
General Data Protection Regulation (GDPR) ,
Health Insurance Portability and Accountability Act (HIPAA) ,
Innovation ,
Life Sciences ,
Machine Learning ,
Medical Devices ,
Mergers ,
Office of Foreign Assets Control (OFAC) ,
Patent-Eligible Subject Matter ,
Pharmaceutical Industry ,
Popular ,
Section 101 ,
USPTO